{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/6a6ca91388c5585c85e9e684?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s","description":"<p>In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice.</p><p><br></p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.&nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>: </p><p><br></p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/stockwatch-axiom-ceo-explains-plans-for-hong-kong-ipo/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: Axiom CEO Explains Plans for Hong Kong IPO&nbsp;</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, July 27, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/latigo-reports-positive-phase-iib-data-for-non-opioid-acute-pain-candidate/\" rel=\"noopener noreferrer\" target=\"_blank\">Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate </a></p><p>By Alex Philippidis, <em>GEN Edge</em>, July 30, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/omics/genetic-study-of-fibromyalgia-points-to-neurological-basis/\" rel=\"noopener noreferrer\" target=\"_blank\">Genetic Study of Fibromyalgia Points to Neurological Basis&nbsp;</a></p><p><em>GEN</em>, July 29, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/genome-editing/base-editing-strategy-alleviates-huntingtons-disease-in-mice/\" rel=\"noopener noreferrer\" target=\"_blank\">Base Editing Strategy Alleviates Huntington’s Disease in Mice&nbsp;</a></p><p><em>GEN</em>, July 29, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a> </p><p>Hosted by Corinna Singleman, PhD </p><p><br></p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a> </p><p>Hosted by Jonathan D. Grinstein, PhD </p><p><br></p><p><a href=\"https://www.genengnews.com/resources/the-state-of-biologics-testing-2026/\" rel=\"noopener noreferrer\" target=\"_blank\">The State of Biologics Testing 2026</a></p><p>Charles River Laboratories and <em>GEN</em>, June 10, 2026</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}